Register for real-time alerts, custom portfolio, and market movers

Get Started

ABBV

AbbVie (ABBV)

AbbVie Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:ABBV

<< Previous 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Next >>

Date	Time	Source	Headline	Symbol	Company
07/03/2024	1:00PM	iHub Newswire	FeaturedFreedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent
07/05/2022	5:26PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
06/29/2022	8:31AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:ABBV	AbbVie Inc
06/29/2022	6:50AM	Dow Jones News	Correction to AbbVie Executives Article on June 28	NYSE:ABBV	AbbVie Inc
06/28/2022	10:06AM	Dow Jones News	AbbVie Names Michael President, Reents Finance Chief	NYSE:ABBV	AbbVie Inc
06/28/2022	9:17AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:ABBV	AbbVie Inc
06/27/2022	8:00AM	PR Newswire (US)	Approximately 15,000 AbbVie Employees to Volunteer Globally to Support Local Communities in Annual Week of Possibilities	NYSE:ABBV	AbbVie Inc
06/27/2022	2:00AM	PR Newswire (US)	CHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis	NYSE:ABBV	AbbVie Inc
06/24/2022	8:51AM	Dow Jones News	Johnson & Johnson's Janssen: CHMP Backs Expanded Imbruvica Use in Chronic Lymphocytic Leukemia	NYSE:ABBV	AbbVie Inc
06/24/2022	8:00AM	PR Newswire (US)	New Survey Offers Perspective on Mental and Emotional Journey for Patients Diagnosed with Slow-Growing Blood Cancer	NYSE:ABBV	AbbVie Inc
06/23/2022	5:08PM	Edgar (US Regulatory)	Annual Report of Employee Stock Plans (11-k)	NYSE:ABBV	AbbVie Inc
06/23/2022	5:07PM	Edgar (US Regulatory)	Annual Report of Employee Stock Plans (11-k)	NYSE:ABBV	AbbVie Inc
06/23/2022	3:43PM	PR Newswire (US)	AbbVie Declares Quarterly Dividend	NYSE:ABBV	AbbVie Inc
06/22/2022	8:00AM	PR Newswire (Canada)	MAVIRET® (glécaprévir/pibrentasvir) : approuvé par Santé Canada dans le traitement de l'hépatite C chronique chez les enfants	NYSE:ABBV	AbbVie Inc
06/22/2022	8:00AM	PR Newswire (Canada)	MAVIRET® (glecaprevir/pibrentasvir) Approved by Health Canada for Paediatric Patients with Chronic Hepatitis C	NYSE:ABBV	AbbVie Inc
06/21/2022	8:00AM	PR Newswire (US)	AbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support Label Expansion for the Preventive Treatment of Migraine	NYSE:ABBV	AbbVie Inc
06/17/2022	9:00AM	PR Newswire (US)	Allergan Aesthetics publishes 'The Future of Aesthetics' global trends report providing unrivalled insight into future of industry	NYSE:ABBV	AbbVie Inc
06/17/2022	8:47AM	Dow Jones News	AbbVie Gets FDA Expanded OK of Skyrizi in Crohn's Disease	NYSE:ABBV	AbbVie Inc
06/17/2022	8:00AM	PR Newswire (US)	SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults	NYSE:ABBV	AbbVie Inc
06/13/2022	8:00AM	GlobeNewswire Inc.	Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics	NYSE:ABBV	AbbVie Inc
06/11/2022	8:45AM	PR Newswire (US)	AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress	NYSE:ABBV	AbbVie Inc
06/10/2022	3:15AM	PR Newswire (US)	AbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients	NYSE:ABBV	AbbVie Inc
06/10/2022	1:05AM	PR Newswire (US)	New Data Demonstrates AbbVie's VENCLYXTO®/VENCLEXTA® Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment	NYSE:ABBV	AbbVie Inc
06/07/2022	8:00AM	PR Newswire (US)	AbbVie to Present Extensive Data from its Migraine Portfolio at the 2022 American Headache Society® (AHS) Annual Scientific Meeting	NYSE:ABBV	AbbVie Inc
06/03/2022	5:45AM	PR Newswire (US)	ABBV SHAREHOLDER ALERT: Jakubowitz Law Reminds AbbVie Shareholders of a Lead Plaintiff Deadline of June 6, 2022	NYSE:ABBV	AbbVie Inc
06/01/2022	10:35AM	PR Newswire (US)	AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022	NYSE:ABBV	AbbVie Inc
06/01/2022	5:45AM	PR Newswire (US)	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of AbbVie Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 6, 2022 - (NYSE: ABBV)	NYSE:ABBV	AbbVie Inc
05/31/2022	5:02PM	Edgar (US Regulatory)	Specialized Disclosure Report (sd)	NYSE:ABBV	AbbVie Inc
05/27/2022	5:45AM	PR Newswire (US)	ABBV SHAREHOLDER ALERT: Jakubowitz Law Reminds AbbVie Shareholders of a Lead Plaintiff Deadline of June 6, 2022	NYSE:ABBV	AbbVie Inc
05/27/2022	3:15AM	PR Newswire (US)	The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis	NYSE:ABBV	AbbVie Inc

Showing the most relevant articles for your search:NYSE:ABBV

<< Previous 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Next >>

Cann American (CE)

1812 Brewing (PK)

Seafarer Exploration (PK)

Net Savings Link (PK)

Voip Pal Com (QB)

Enzolytics (PK)

Digital Brand Media and ... (PK)

Virexit Technologies (PK)

Branded Legacy (PK)

Ubiquitech Software (PK)

Delayed Upgrade Clock